^
    Back
    Association details:
    Biomarker:TRIM33-RET fusion
    Cancer:Sarcoma
    Drug:Retevmo (selpercatinib) (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Cancer Res Clin Oncol
    Title:

    Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma

    Published date:
    12/05/2022
    Excerpt:
    Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas.
    DOI:
    10.1007/s00432-022-04496-y